Penn State Cancer Institute at Milton S. Hershey Medical Center
Hershey, Pennsylvania, 17033-0850, United States
NCT Number: NCT00109941
RATIONALE: Opioid growth factor may stop the growth of pancreatic cancer by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well opioid growth factor works in treating patients with advanced pancreatic cancer that cannot be removed by surgery.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 2
Hershey, Pennsylvania, 17033-0850, United States
OBJECTIVES:
Primary
Secondary
OUTLINE: This is an open-label study.
Patients receive opioid growth factor ([Met^5]-enkephalin) IV over 45 minutes once weekly. Treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 4 weeks during study treatment, and at the completion of study treatment.
Patients are followed weekly for survival.
PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
Other names: Opioid growth factor or OGF is a 5 amino acid peptide
OGF given in saline iv 250 ug/kg weekly
Other names: opioid growth factor
Milton S. Hershey Medical Center
Other
Treatment of Advanced Pancreatic Cancer With Opioid Growth Factor (OGF): Phase II
Acronym: OGF
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05675059
Digestive System Diseases, Digestive System Neoplasms
Tampa, Florida, United States
View Trial DetailsNCT03410030
Digestive System Diseases, Digestive System Neoplasms
Scottsdale, Arizona, United States
View Trial DetailsNCT04553926
Adnexal Diseases, Breast Cancer
Ansan, South Korea
View Trial DetailsNCT03096054
Breast Cancer (Triple Negative Type), Breast Diseases
Belfast, United Kingdom
View Trial Details